News

CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing

Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7%) experience at least one major depressive

Vitae discovers and develops small molecule drugs for diseases with significant unmet medical needs. The company uses its structure-based drug design platform, Contour, for discovering a portfolio of

Pharmatek, founded in 1999, offers dosage form development and clinical-scale cGMP manufacturing of oral, injectable and topical products for over 100 customers globally. The acquisition will add discovery-to-clinic

These two large outcome trials will help to define the potential role of dapagliflozin in the management of chronic kidney disease and chronic heart failure respectively, in people

Biological therapeutics represented seven of the top ten best selling drugs of 2015, and they feature extensively in developmental pipelines. Access to bioproduction cell lines for their manufacture

US biopharmaceutical firm Exelixis discovered and developed Cabometyx, which is claimed to be the first and only therapy approved in the European Union to demonstrate enhanced overall survival,

MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda’s decision comes earlier than the predefined expiration of its option exercise period

"XmAb14045 is a bispecific antibody that engages the immune system against AML," said Paul Foster, M.D., chief medical officer at Xencor. "Built on the scaffold of Xencor's XmAb